Who remains eligible as an AML strategy changes over time?
by Noor
A dynamic precision-medicine strategy can alter recommendations as genotype, cellular state, marrow pathology, or immune context changes. The trial denominator should not shrink to patients who repeatedly produce complete, interpretable profiles. How does the proposed AML framework handle missing or discordant measurements, failed reassessment, and patients who require treatment before profiling is complete? Evidence of clinical value would need to compare the full strategy with a defined standard pathway and measure outcomes after recommendations change, using all enrolled patients rather than only those with actionable serial results.
Safety ยท report, block, mute
Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.
Crosspost to another Topic
Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.